Portal de Periódicos da CAPES

Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial

2013; Elsevier BV; Volume: 112; Issue: 2 Linguagem: Inglês

10.1016/j.anai.2013.11.018

1534-4436

Jennifer Maloney, David I. Bernstein, Harold S. Nelson, Peter S. Creticos, Jacques Hébert, Michael Noonan, David P. Skoner, Yijie Zhou, Amarjot Kaur, Hendrik Nolte,

Respiratory and Cough-Related Research

Background In North America, few studies have evaluated sublingual immunotherapy for allergic rhinitis with or without conjunctivitis (AR/C); pediatric data are sparse. The authors report findings from the largest published immunotherapy trial yet conducted in adults and children. Objective To evaluate grass sublingual immunotherapy tablet (MK-7243) treatment in subjects with AR/C. Methods North American subjects (5–65 years old) with grass allergy were randomized 1:1 to once-daily MK-7243 (2,800 BAU Phleum pratense) or placebo. The first dose was given at the investigator's office; subsequent doses were self-administered at home. The primary end point was total combined score (TCS; rhinoconjunctivitis daily symptom score [DSS] plus daily medication score [DMS]) over the entire grass pollen season (GPS). Key secondary end points included entire-season DSS, DMS, peak-season TCS, and rhinoconjunctivitis quality-of-life questionnaire scores. Safety outcomes included adverse events (AEs). Results One thousand five hundred one subjects were randomized (85% polysensitized, 25% had asthma). MK-7243 yielded improvements vs placebo of 23% in entire-season TCS (median difference −0.98, P < .001), 29% in peak-season TCS (median difference −1.33, P < .001), 20% in entire-season DSS (median difference −0.64, P = .001), 35% in entire-season DMS (mean difference −0.48, P < .001), and 12% in peak-season rhinoconjunctivitis quality-of-life questionnaire (median difference −0.13, P = .027). Efficacy between children and adults was similar. Most AEs were transient local application-site reactions, with no serious treatment-related AEs or anaphylactic shock. Three subjects (1 placebo, 2 MK-7243) had moderate systemic allergic reactions. Conclusion MK-7243 was effective in polysensitized grass-allergic North American children and adults with AR/C in this large trial, confirming previous research.